Mitem Pharma acquired from Novartis worldwide rights to Desferal, commonly used to lower excessive iron levels induced by ...

Columnist Mary Shaniqua, returning from her post-wedding activities, has learned that stepping back from advocacy obligations ...

The stroke rate among adults and children with sickle cell disease in the U.S. is rising, indicating a need for greater ...

Pfizer has voluntarily withdrawn Oxbryta (voxelotor), a conditionally approved oral therapy for sickle cell disease (SCD), from worldwide markets, saying clinical data shows the treatment’s benefit ...